Although many aspects of HEV biology are still to be unraveled, the recent findings that lymphotoxin-β receptor-dependent signaling in EC is critical for the development and function of HEV are significant advances in our understanding and may provide therapeutic approaches to promote HEV neogenesis in tumors and determine the impact on HEV on tumor immunity. This evidence concerns the gene LTBR and neoplasm.